Reduction of serum lipids by the intake of the extract of garlic fermented with Monascus pilosus: A randomized, double-blind, placebo-controlled clinical trial

Clinical Nutrition

Volumn 31, Issue 2, 2012, Pages 261-266

  Higashikawa, Fumiko ^a,b   Noda, Masafumi ^a,b   Awaya, Tomokazu ^c   Ushijima, Mitsuyasu ^d   Sugiyama, Masanori ^a,b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^d WAKUNAGA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Dimerumic acid; Garlic; Monacolin K; Monascus pilosus; Serum lipids

Indexed keywords

GARLIC EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BODY FAT DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; EXTRACTIVE FERMENTATION; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MONASCUS PILOSUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; CHOLESTEROL; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FERMENTATION; FOOD HANDLING; GARLIC; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MONASCUS; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; PLANT EXTRACTS; TRIGLYCERIDES; YOUNG ADULT;

EID: 84858752849     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2011.10.008     Document Type: Article

References (30)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival study (4S). Lancet 1994, 344:1383-1389.
2. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 1995, 333:1301-1307.
3. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA 1998, 279:1615-1622.
4. Moghadasian M.H. A safety look at currently available statins. Expert Opin Drug Saf 2002, 1:269-274.
5. Bolego C., Baetta R., Bellosta S., Corsini A., Paoletti R. Safety considerations for statins. Curr Opin Lipidol 2002, 13:637-644.
6. Bellosta S., Paoletti R., Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004, 109(23 Suppl. 1):III50-III57.
7. Endo A. Monacolin K, a new hypocholesterolemic agent produced by a monascus species. J Antibiot (Tokyo) 1979, 32:852-854.
8. Endo A. Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme a reductase. J Antibiot (Tokyo) 1980, 33:334-336.
9. Heber D., Yip I., Ashley J.M., Elashoff D.A., Elashoff R.M., Go V.L. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999, 69:231-236.
10. Liu J., Zhang J., Shi Y., Grimsgaard S., Alraek T., Fønnebø V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 2006, 1:4.
11. Guardamagna O., Abello F., Baracco V., Stasiowska B., Martino F. The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr Metab Cardiovasc Dis 2011, 21:424-429.
12. Affuso F., Ruvolo A., Micillo F., Saccà L., Fazio S. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis 2010, 20:656-661.
13. Heber D., Lembertas A., Lu Q.Y., Bowerman S., Go V.L. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 2001, 7:133-139.
14. Klimek M., Wang S., Ogunkanmi A. Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. PT 2009, 34:313-327.
15. Gordon R.Y., Cooperman T., Obermeyer W., Becker D.J. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware!. Arch Intern Med 2010, 25(170):1722-1727.
16. Harris J.C., Cottrell S.L., Plummer S., Lloyd D. Antimicrobial properties of Allium sativum (garlic). Appl Microbiol Biotechnol 2001, 57:282-286.
17. Tattelman E. Health effects of garlic. Am Fam Physician 2005, 72:103-106.
18. Sato T., Miyata G. The nutraceutical benefit, part IV: garlic. Nutrition 2000, 16:787-788.
19. Ngo S.N., Williams D.B., Cobiac L., Head R.J. Does garlic reduce risk of colorectal cancer? A systematic review. J Nutr 2007, 137:2264-2269.
20. Khoo Y.S., Aziz Z. Garlic supplementation and serum cholesterol: a meta-analysis. J Clin Pharm Ther 2009, 34:133-145.
21. Ackermann R.T., Mulrow C.D., Ramirez G., Gardner C.D., Morbidoni L., Lawrence V.A. Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med 2001, 161:813-824.
22. Reinhart K.M., Talati R., White C.M., Coleman C.I. The impact of garlic on lipid parameters: a systematic review and meta-analysis. Nutr Res Rev 2009, 22:39-48.
23. Steiner M., Khan A.H., Holbert D., Lin R.I. A double-blind crossover study in moderately hypercholesterolemic men that compared the effect of aged garlic extract and placebo administration on blood lipids. Am J Clin Nutr 1996, 64:866-870.
24. Sumioka I., Hayama M., Shimokawa Y., Shiraishi S., Tokunaga A. Lipid-lowering effect of monascus garlic fermented extract (MGFE) in hyperlipidemic subjects. Hiroshima J Med Sci. 2006, 55:59-64.
25. Ramasubbu K., Estep J., White D.L., Deswal A., Mann D.L. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008, 51:415-426.
26. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001, 21:1712-1719.
27. Rikitake Y., Kawashima S., Takeshita S., Yamashita T., Azumi H., Yasuhara M. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001, 154:87-96.
28. Aniya Y., Ohtani, Higa T., Miyagi C., Gibo H., Shimabukuro M. Dimerumic acid as an antioxidant of the mold, monascus anka. Free Radic Biol Med 2000, 28:999-1004.
29. Taira J., Miyagi C., Aniya Y. Dimerumic acid as an antioxidant from the mold, monascus anka: the inhibition mechanisms against lipid peroxidation and hemeprotein-mediated oxidation. Biochem Pharmacol 2002, 63:1019-1026.
30. Yamashiro J., Shiraishi S., Fuwa T., Horie T. Dimerumic acid protected oxidative stress-induced cytotoxicity in isolated rat hepatocytes. Cell Biol Toxicol 2008, 24:283-290.